FULVESTRANT

Details

Stereochemistry	EPIMERIC
Molecular Formula	C32H47F5O3S
Molecular Weight	606.771
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 7
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]3([H])C4=C(C[C@@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)[C@@]23[H])C=C(O)C=C4

InChI

InChIKey=VWUXBMIQPBEWFH-WCCTWKNTSA-N

InChI=1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1

HIDE SMILES / InChI

Molecular Formula	C32H47F5O3S
Molecular Weight	606.771
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.drugbank.ca/drugs/DB00947
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/ppa/fulvestrant.html

Fulvestrant is a drug treatment of hormone receptor-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. Fulvestrant competitively and reversibly binds to estrogen receptors present in cancer cells and achieves its anti-estrogen effects through two separate mechanisms. First, fulvestrant binds to the receptors and downregulates them so that estrogen is no longer able to bind to these receptors. Second, fulvestrant degrades the estrogen receptors to which it is bound. Both of these mechanisms inhibit the growth of tamoxifen-resistant as well as estrogen-sensitive human breast cancer cell lines. Fulvestrant is used for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. Fulvestrant is marketed under the trade name Faslodex, by AstraZeneca.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Estrogen receptor alpha 127 Target ID: CHEMBL206 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26407012	Antagonist 2778		0.0631 nM [IC50]
MCF7 21 Target ID: CHEMBL387 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26407012	Inhibitor 8297		0.1 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hormone receptor positive metastatic breast cancer 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021344s015lbl.pdf	Primary		Approved 8429	FASLODEX Approved Use FASLODEX is an estrogen receptor antagonist indicated for the: Treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Launch Date 2002

C_max

Value	Dose	Co-administered	Analyte	Population
25.1 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021344Orig1s039lbl.pdf	500 mg single, intramuscular dose: 500 mg route of administration: Intramuscular experiment type: SINGLE co-administered:		FULVESTRANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
11400 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021344Orig1s039lbl.pdf	500 mg single, intramuscular dose: 500 mg route of administration: Intramuscular experiment type: SINGLE co-administered:		FULVESTRANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
40 day DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021344Orig1s039lbl.pdf	250 mg single, intramuscular dose: 250 mg route of administration: Intramuscular experiment type: SINGLE co-administered:		FULVESTRANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
500 mg 1 times / month multiple, intramuscular Highest studied dose Dose: 500 mg, 1 times / month Route: intramuscular Route: multiple Dose: 500 mg, 1 times / month Sources: https://pubmed.ncbi.nlm.nih.gov/29901634	unhealthy, 54 years n = 1 Health Status: unhealthy Condition: breast cancer Age Group: 54 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/29901634	Sources: https://pubmed.ncbi.nlm.nih.gov/29901634
500 mg 1 times / month multiple, intramuscular Dose: 500 mg, 1 times / month Route: intramuscular Route: multiple Dose: 500 mg, 1 times / month Sources: https://pubmed.ncbi.nlm.nih.gov/33261799	unhealthy, 56 years n = 1 Health Status: unhealthy Condition: ductal carcinoma of the breast Age Group: 56 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/33261799	Disc. AE: Epidermal necrolysis... AEs leading to discontinuation/dose reduction: Epidermal necrolysis (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/33261799

AEs

AE	Significance	Dose	Population
Epidermal necrolysis	1 patient Disc. AE	500 mg 1 times / month multiple, intramuscular Dose: 500 mg, 1 times / month Route: intramuscular Route: multiple Dose: 500 mg, 1 times / month Sources: https://pubmed.ncbi.nlm.nih.gov/33261799	unhealthy, 56 years n = 1 Health Status: unhealthy Condition: ductal carcinoma of the breast Age Group: 56 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/33261799

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587 inducer 781	inhibitor 1767 inducer 389	inhibitor 1852 inducer 97

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2C19 1478	UGT1A1 418 UGT1A3 422 UGT1A4 347 UGT1A8 283	CYP1A2 701 CYP2C19 293

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-344_Fulvestrant_biopharmr.pdf#page=21 Page: 21,22	no
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-344_Fulvestrant_biopharmr.pdf#page=21 Page: 21,22	no
CYP2C19 1553	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-344_Fulvestrant_biopharmr.pdf#page=21 Page: 21,22	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-344_Fulvestrant_biopharmr.pdf#page=21 Page: 21,22	no
CYP2C9 1819	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-344_Fulvestrant_biopharmr.pdf#page=21 Page: 21,22	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-344_Fulvestrant_biopharmr.pdf#page=21 Page: 21,22	no
CYP2D6 1891	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-344_Fulvestrant_biopharmr.pdf#page=21 Page: 21,22	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-344_Fulvestrant_biopharmr.pdf#page=21 Page: 21,22	no
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-344_Fulvestrant_biopharmr.pdf#page=21 Page: 21,22	no	weak (co-administration study) Comment: fulvestrant increased midazolam AUC by 11% but decreased Cmax by 25% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-344_Fulvestrant_biopharmr.pdf#page=21 Page: 21,22
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-344_Fulvestrant_biopharmr.pdf#page=21 Page: 21,22	no	weak (co-administration study) Comment: fulvestrant increased midazolam AUC by 11% but decreased Cmax by 25% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-344_Fulvestrant_biopharmr.pdf#page=21 Page: 21,22

Drug as victim

Target	Modality	Activity	Clinical evidence
UGT1A1 418	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16339389/	yes
UGT1A3 422	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16339389/	yes
UGT1A4 347	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16339389/	yes
UGT1A8 283	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16339389/	yes
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-344_Fulvestrant_biopharmr.pdf#page=21 Page: 21.0	yes	no (co-administration study) Comment: label: administration with rifampin (inducer) showed not effect on PK of fulvestrant Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-344_Fulvestrant_biopharmr.pdf#page=21 Page: 21.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:31638	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31638
ChemicalBook	CB0698542	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0698542
Selleck Chemicals	Fulvestrant	http://www.selleckchem.com/products/Fulvestrant.html
eMolecules	6719147	https://www.emolecules.com/cgi-bin/more?vid=6719147

PubMed

Title	Date	PubMed
Estrogenicity of bisphenol A in a human endometrial carcinoma cell line.	1999 Apr 25	10411312
Methoxychlor stimulates estrogen-responsive messenger ribonucleic acids in mouse uterus through a non-estrogen receptor (non-ER) alpha and non-ER beta mechanism.	1999 Aug	10433208
Estrogen directly respresses gonadotropin-releasing hormone (GnRH) gene expression in estrogen receptor-alpha (ERalpha)- and ERbeta-expressing GT1-7 GnRH neurons.	1999 Nov	10537130
The aryl hydrocarbon receptor (AHR)/AHR nuclear translocator (ARNT) heterodimer interacts with naturally occurring estrogen response elements.	1999 Nov 25	10619402
Relative binding affinity does not predict biological response to xenoestrogens in rat endometrial adenocarcinoma cells.	2000 Oct	11086226
Modulation of aromatase expression in human breast tissue.	2001 Dec	11850205
Infertility and testicular atrophy in the antiestrogen-treated adult male rat.	2001 Sep	11514358
Comparison of an array of in vitro assays for the assessment of the estrogenic potential of natural and synthetic estrogens, phytoestrogens and xenoestrogens.	2001 Sep 14	11518614
Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.	2001 Sep 15	11559545
Inhibition of E2-induced expression of BRCA1 by persistent organochlorines.	2002	12473173
Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor.	2002 Aug 1	12154049
Stimulation of alkaline phosphatase activity in Ishikawa cells induced by various phytoestrogens and synthetic estrogens.	2002 Dec	12650720
Modulation of estrogen receptor-dependent reporter construct activation and G0/G1-S-phase transition by polycyclic aromatic hydrocarbons in human breast carcinoma MCF-7 cells.	2002 Dec	12441364
Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7.	2002 Jan	11867264
Estradiol enhances and estriol inhibits the expression of CYP1A1 induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in a mouse ovarian cancer cell line.	2002 Jul 15	12093619
Organochlorine pesticides directly regulate gonadotropin-releasing hormone gene expression and biosynthesis in the GT1-7 hypothalamic cell line.	2002 Jun 28	12088877
17-epiestriol, an estrogen metabolite, is more potent than estradiol in inhibiting vascular cell adhesion molecule 1 (VCAM-1) mRNA expression.	2003 Apr 4	12547825
Cadmium mimics the in vivo effects of estrogen in the uterus and mammary gland.	2003 Aug	12858169
The aryl hydrocarbon receptor mediates degradation of estrogen receptor alpha through activation of proteasomes.	2003 Mar	12612060
Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER alpha.	2003 May 1	12594813
Induction of the paraoxonase-1 gene expression by resveratrol.	2004 Dec	15458977
Augmented endothelial nitric oxide synthase (eNOS) protein expression in human pregnant myometrium: possible involvement of eNOS promoter activation by estrogen via both estrogen receptor (ER)alpha and ERbeta.	2004 Feb	14742696
Oestrogen receptor beta is required for androgen-stimulated proliferation of LNCaP prostate cancer cells.	2004 Jun	15171712
Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation.	2004 Mar 20	14750165
Small nuclear RING finger protein expression during gonad development: regulation by gonadotropins and estrogen in the postnatal ovary.	2004 May	14749358
Xenoestrogen-induced ERK-1 and ERK-2 activation via multiple membrane-initiated signaling pathways.	2004 Nov	15531431
Proliferation-stimulating effects of icaritin and desmethylicaritin in MCF-7 cells.	2004 Nov 19	15541416
Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells.	2005	16168102
Transcriptional activation of the oxytocin promoter by oestrogens uses a novel non-classical mechanism of oestrogen receptor action.	2005 Apr	15842231
Alternative splicing of Slo channel gene programmed by estrogen, progesterone and pregnancy.	2005 Aug 29	16102753
Co-culture of primary human mammary fibroblasts and MCF-7 cells as an in vitro breast cancer model.	2005 Feb	15525692
Opposite effects of estrogen receptors alpha and beta on MCF-7 sensitivity to the cytotoxic action of TNF and p53 activity.	2005 Jul 14	15870704
Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release.	2005 Jul 15	15950373
Receptor isoform and ligand-specific modulation of dihydrotestosterone-induced prostate specific antigen gene expression and prostate tumor cell growth by estrogens.	2005 Jul-Aug	15955889
Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells.	2005 Jun	15930183
Differential effects of estrogens and progestins on the anticoagulant tissue factor pathway inhibitor in the rat.	2005 Mar	15857755
Estrogen increases mitochondrial efficiency and reduces oxidative stress in cerebral blood vessels.	2005 Oct	15994367

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Breast Cancer Initial dose: 500 mg IM on days 1, 15, and 29, then once a month thereafter.

Route of Administration: Intramuscular

In Vitro Use Guide

In human and rat mesangial cells, increased type IV collagen and fibronectin gene transcription induced by TGF-b1 was downregulated by Fulvestrant at concentrations ranging from 10(-10) M to 10(-7) M.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:51:42 GMT 2023` Edited by `admin` on `Fri Dec 15 15:51:42 GMT 2023`
Record UNII	22X328QOC4
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FULVESTRANT

Official Name

English

FULVESTRANT [MART.]

Common Name

English

ZD-9238

Code

English

FULVESTRANT [MI]

Common Name

English

FULVESTRANT [USP-RS]

Common Name

English

FULVESTRANT [VANDF]

Common Name

English

FULVESTRANT [USP IMPURITY]

Common Name

English

Fulvestrant [WHO-DD]

Common Name

English

FASLODEX

Brand Name

English

ICI-182780

Code

English

FULVESTRANT [JAN]

Common Name

English

FULVESTRANT [ORANGE BOOK]

Common Name

English

NSC-759879

Code

English

FULVESTRANT [USP MONOGRAPH]

Common Name

English

ESTRA-1,3,5(10)-TRIENE-3,17-DIOL, 7-(9-((4,4,5,5,5-PENTAFLUOROPENTYL)SULFINYL)NONYL)-, (7.ALPHA.,17.BETA.)-

Systematic Name

English

fulvestrant [INN]

Common Name

English

ZD9238

Code

English

ICI 182,780

Code

English

FULVESTRANT [EP MONOGRAPH]

Common Name

English

FULVESTRANT [EMA EPAR]

Common Name

English

7.ALPHA.-(9-(4,4,5,5,5-PENTAFLUOROPENTYLSULPHINYL)NONYL)ESTRA-1,3,5(10)-TRIENE-3,17.BETA.-DIOL

Systematic Name

English

FULVESTRANT [USAN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QL02BA03